Peer-reviewed scientific literature is the unit of trust in this field. Marketing copy is not. Verified Compounds is built on the conviction that a reagent supplier should publish the evidence — not the testimonial — and that an investigator should be able to see documentation status before committing the purchase order.
What follows is the editorial standard Verified Compounds holds itself to. None of it is unusual in the analytical literature. Most of it is unusual in this market.
Pillar I. Released-lot documentation status
Product pages should show whether lot-specific documentation is released, pending, or not applicable to the current launch state. An investigator is not asked to trust a generic percentage in a marketing claim; unreleased documentation remains marked pending.
When a lot record is released, the product page can attach the lot number and COA packet. Historical documentation should remain accessible from the order record for every investigator who purchased that lot.
Pillar II. Primary-literature citation pack per SKU
Each compound ships with a bundled PDF of the primary literature relevant to its chemistry. Author, journal, year, and the observation as published are reported in chemistry context — for example, the receptor-binding affinities described in the research literature on the growth-hormone-releasing peptide series, or the structural characterization of the Khavinson short-peptide bioregulators.
The citation pack is a literature index, not a protocol. It does not recommend a dose, a route, or a use. It documents what has been reported about the molecule so that the investigator can decide whether and how the reagent fits a planned in-vitro experiment.
Pillar III. Chain-of-custody documentation
Anonymous or generic COAs are a problem in this market. The intended release model is a lot-specific documentation packet that identifies the relevant lot and analytical context instead of relying on a stock certificate image.
Batch records and released documentation should remain available to the purchasing institution through the order record or written support request.
Pillar IV. Verified principal-investigator accounts
A research profile gates the catalog. Verified investigators receive purchase-order and Net-30 terms on institutional orders, ACH payment above a configurable threshold, and released-lot documentation in the order packet when available. Account verification is a human-reviewed step. The reagent is sold to a named investigator, on the record.
Pillar V. The Reference
The editorial library on this site — The Reference — collects the chemistry literature by structural family. The body protection compound family, the glucagon-family analogs, the thymic-origin peptides, the melanocortin analogs, the Khavinson short-peptide bioregulators, the mitochondrial-localized peptides. Each section is a literature index: papers as reported, in chemistry context, without interpretation, without protocol.
The Reference is a public resource. It exists because the alternative — anonymous mechanism claims dressed as marketing — has degraded this market. Verified Compounds would rather cite the literature carefully than describe it loosely.
A note on what is not done here
Verified Compoundsdoes not write dosing guides, publish suggested-use protocols, organize the catalog by therapeutic area, or describe what a compound “does to a person.” The molecule is the molecule; the literature is the literature; the experiment is the investigator's.
Restraint is not modesty. It is the position from which a reagent supplier earns the trust of the people who use the reagents.